The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
The two doses of sodium bicarbonate being tested are 0.5 and 0.8 mEq/kg-lean body weight
(LBW) per day. Sodium bicarbonate, also known as baking soda, may help prevent kidney failure
in people with chronic kidney disease. However, the dose to prescribe in order to test this
possibility in a clinical trial is uncertain. The BASE pilot clinical trial will help
determine the best dose of sodium bicarbonate to prescribe in a future study that will test
the long-term safety and efficacy of sodium bicarbonate as a treatment to preserve kidney
function in individuals with chronic kidney disease.
Phase:
Phase 3
Details
Lead Sponsor:
Jennifer Gassman, PhD John Kusek
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) The Cleveland Clinic